Trial Profile
A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2014
Price :
$35
*
At a glance
- Drugs Timapiprant (Primary)
- Indications Eosinophilic oesophagitis
- Focus Pharmacodynamics; Proof of concept
- Sponsors Oxagen
- 28 Aug 2014 New trial record